PMID- 31468315
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200309
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 79
IP  - 13
DP  - 2019 Sep
TI  - Glycopyrronium/Formoterol: A Review in COPD.
PG  - 1455-1466
LID - 10.1007/s40265-019-01186-x [doi]
AB  - Glycopyrronium/formoterol (Bevespi Aerosphere((R))) is a fixed-dose combination of 
      the long-acting muscarinic antagonist glycopyrronium bromide and the long-acting 
      beta(2)-agonist formoterol fumarate delivered via a pressurized metered dose inhaler 
      (pMDI) and formulated using co-suspension delivery technology. It is approved in 
      the USA and EU for use as maintenance treatment in patients with chronic 
      obstructive pulmonary disease (COPD) and in Japan to relieve symptoms in patients 
      with COPD. In the PINNACLE trials in patients with moderate to very severe COPD, 
      glycopyrronium/formoterol was associated with significantly greater improvements 
      in lung function than its monocomponents and placebo at 24 weeks and its 
      monocomponents and open-label tiotropium over 52 weeks. In the AERISTO trial, 
      glycopyrronium/formoterol was non-inferior to umeclidinium/vilanterol dry powder 
      inhaler for peak change in forced expiratory volume in 1 s (FEV(1)) within 2 h 
      postdose, but not for the change in morning predose trough FEV(1), over 24 weeks. 
      Glycopyrronium/formoterol was generally well tolerated in patients with moderate 
      to very severe COPD, with most adverse events (AEs) being of mild or moderate 
      severity. Thus, glycopyrronium/formoterol pMDI formulated using co-suspension 
      delivery technology is a useful new addition that extends treatment options for 
      patients with COPD.
FAU - Al-Salama, Zaina T
AU  - Al-Salama ZT
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Frampton, James E
AU  - Frampton JE
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Adjuvants, Anesthesia)
RN  - 0 (Bronchodilator Agents)
RN  - V92SO9WP2I (Glycopyrrolate)
RN  - W34SHF8J2K (Formoterol Fumarate)
SB  - IM
MH  - Adjuvants, Anesthesia/*therapeutic use
MH  - Animals
MH  - Bronchodilator Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Formoterol Fumarate/*therapeutic use
MH  - Glycopyrrolate/*therapeutic use
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
EDAT- 2019/08/31 06:00
MHDA- 2020/01/30 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2019/08/31 06:00 [entrez]
AID - 10.1007/s40265-019-01186-x [pii]
AID - 10.1007/s40265-019-01186-x [doi]
PST - ppublish
SO  - Drugs. 2019 Sep;79(13):1455-1466. doi: 10.1007/s40265-019-01186-x.